Listenly

Why does the location of a CDMO facility impact drug delivery to market?

Answered at 11:00 in Why Procurement Can Make or Break a Drug Company · Executive Edge Podcast

— questions searchable right now

Why does the location of a CDMO facility impact drug delivery to market?

The CDMO location is critical because it affects logistics parameters like cold chain requirements, transport time, and half-life stability of the drug. For example, a radioisotope with a five-day half-life produced in Indiana must reach patients within that timeframe, making facility location a major factor in market access.

Dave Stowe on Executive Edge PodcastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

The CDMO location is critical because it affects logistics parameters like cold chain requirements, transport time, and half-life stability of the drug.

Dave Stowe, Founder and Managing Partner at Adventus · Why Procurement Can Make or Break a Drug Company · Executive Edge Podcast · answer at 11:00

Key takeaways

  • The CDMO location is critical because it affects logistics parameters like cold chain requirements, transport time, and half-life stability of the drug.

Quote to remember

“There's always this challenge, right? It's a game of capacity management. You know, you can imagine you're buying capacity at the CDMO. They could sell it to somebody else.”

— Dave Stowe

The full answer · about 2 min

The CDMO location is critical because it affects logistics parameters like cold chain requirements, transport time, and half-life stability of the drug. For example, a radioisotope with a five-day half-life produced in Indiana must reach patients within that timeframe, making facility location a major factor in market access.

Key facts

  • 37% of global chemicals in pharmaceutical manufacturing originate from China
  • CDMO biologics manufacturing forecasted at 8 to 12% compound annual growth rate over seven years
  • Drug development timeline: 2 to 5 to 10 years from preclinical through full production
  • Radioisotope half-life example: 5-day half-life requiring overnight shipping from Indiana to patient administration
  • Injectable syringe viscosity requirement: under 5 to 10 milliliters

People, companies and topics mentioned

AdventusCDMO (Contract Development Manufacturing Organization)FDA (Food and Drug Administration)PwCOliver WymanHorizon TherapeuticsPurdue PharmaKSM (Key Starting Materials)

More answers from this episode

 ·  All answers from Executive Edge Podcast →
—
—
0:00
0:00